Genetic disorders at the heart of the analysis
mTORopathies are genetic disorders in which mutations disrupt mTOR signaling. This pathway is involved in the mechanisms of epilepsy, but its role in human status epilepticus remains poorly understood, according to the authors.
The researchers conducted a systematic search of PubMed, Embase and Web of Science. Of 897 references initially identified, 31 publications were included to examine clinical manifestations, treatments and reported outcomes.
The source material provides access only to the PubMed abstract. It does not specify the total number of patients, follow-up durations or the detailed breakdown of the different disorders studied.
Resistant forms that are particularly difficult to treat
According to the review, status epilepticus can occur in various mTORopathies. It often begins early and frequently recurs. Refractory, treatment-resistant forms mainly affect newborns and infants and often occur in the context of malformations of cortical development.
The authors report that antiseizure medications, used alone or with mTOR inhibitors, may stop status epilepticus. However, the abstract provides no success rates or comparisons that would isolate the benefit of mTOR inhibitors.
The strategies identified also include anesthetics, the ketogenic diet, immunotherapy, epilepsy surgery and neuromodulation. This list describes specialized care approaches, not options whose efficacy is equivalent or established for every patient.
A biological target, not yet an established answer
The authors favor an approach combining several treatment modalities to control seizures and improve developmental outcomes. However, the abstract does not allow these improvements to be quantified or establish which combination would be preferable.
The key distinction is this: the biological involvement of mTOR justifies further research, but does not demonstrate that inhibiting this pathway improves clinical outcomes. The authors call for large cohort studies to clarify its role and evaluate mTOR inhibitors as well as immunotherapies.
Limitations to keep in mind
Analysis based solely on the PubMed abstract, without consulting the full text. Patient numbers, comparators, quantified effects and the quality of the included publications are not detailed in the excerpt. Funding and conflicts of interest could not be verified. These observations should not be generalized to all epilepsies.
What we can take away
This review documents a major clinical challenge in specific genetic disorders. It does not establish the efficacy of mTOR inhibitors against status epilepticus.
Sources and provenance
- Status epilepticus in mTORopathies: a systematic review of clinical features, management, and outcomes.
Source date: 2026-11-16.
Journal Article, Systematic Review, Review · Résumé PubMed uniquement, texte intégral non consulté


